Search results for "topoi"

showing 10 items of 701 documents

SARS‐CoV ‐2‐reactive antibody detection after SARS‐CoV ‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the S…

2021

This is a multicenter prospective observational study which included a large cohort (n = 397) of allogeneic (allo-HSCT) (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3 to 6 weeks after complete SARS-CoV-2 vaccination from February 1st 2021 to July 20th 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopenia <1x109 /mL [Odds ratio (OR…

Oncologymedicine.medical_specialtybiologybusiness.industrymedicine.medical_treatmentHematopoietic stem cellHematologyDiseaseOdds ratioHematopoietic stem cell transplantationmedicine.diseaseLymphomaCell therapyVaccinationmedicine.anatomical_structureInternal medicinemedicinebiology.proteinAntibodybusinessAmerican Journal of Hematology
researchProduct

Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transpla…

2020

The net impact of cytomegalovirus (CMV) DNAemia on overall mortality (OM) and nonrelapse mortality (NRM) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a matter of debate. This was a retrospective, multicenter, noninterventional study finally including 749 patients. CMV DNA monitoring was conducted by real-time polymerase chain reaction (PCR) assays. Clinical outcomes of interest were OM and NRM through day 365 after allo-HSCT. The cumulative incidence of CMV DNAemia in this cohort was 52.6%. A total of 306 out of 382 patients with CMV DNAemia received preemptive antiviral therapy (PET). PET use for CMV DNAemia, but not the occurrence of CMV DNAemia, taken …

Oncologymedicine.medical_specialtybone marrowinfection and infectious agents - viralmedicine.medical_treatmentCongenital cytomegalovirus infectionCytomegaloviruscomplicationHematopoietic stem cell transplantation030230 surgerylaw.inventionCell therapy03 medical and health sciences0302 clinical medicinelawInternal medicinehemic and lymphatic diseasesRisk of mortalityImmunology and AllergyMedicineHumansTransplantation HomologousPharmacology (medical)Cumulative incidencePolymerase chain reactionRetrospective StudiesTransplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesmedicine.diseasepracticeTransplantationinfectious infection and infectious agents - viral: Cytomegalovirus (CMV) [bone marrow/hematopoietic stem cell transplantation clinical research/practice complication]infectiousclinical researchCohortCytomegalovirus InfectionsDNA Viralhematopoietic stem cell transplantationCytomegalovirus (CMV)business
researchProduct

Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refr…

2019

Background: Venetoclax (Ven) is a highly selective, potent, oral BCL-2 inhibitor that induces apoptosis in multiple myeloma (MM) cells and has shown synergistic activity with the proteasome inhibitor (PI) bortezomib (B) and dexamethasone (d). Ven ± d had encouraging clinical efficacy in both t(11;14) MM and in pts irrespective of genetic background when administered with B, with a tolerable safety profile in Phase 1 studies. Here, we provide updated efficacy and safety of Ven vs placebo (Pbo) + Bd in pts with relapsed/refractory (RR) MM, including subgroup analyses, in the BELLINI study. Methods: BELLINI (NCT02755597) was a Phase 3, randomized, double-blind, multicenter study of Ven or Pbo…

Oncologymedicine.medical_specialtybusiness.industryBortezomibVenetoclaxmedicine.medical_treatmentImmunologyPhases of clinical researchCell BiologyHematologyHematopoietic stem cell transplantationNeutropeniamedicine.diseasePlaceboBiochemistrychemistry.chemical_compoundchemistryInternal medicineMedicinebusinessMultiple myelomaDexamethasonemedicine.drugBlood
researchProduct

Related versus unrelated donor transplantation for high risk (HiRi) acute myeloid leukemia (AML) in first complete remission (CR1)

2007

Abstract Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-identical sibling donor (SIB) is considered the preferred postremission therapy for younger patients with HiRi AML in CR1. The role of allo-SCT from volunteer unrelated donors (VUDs) is less clear and randomized controlled trials addressing this issue do not exist. We performed an observational landmark analysis on parallel cohorts of patients aged &amp;lt;60 years with AML in CR1 and HiRi cytogenetics who had been enrolled into the AML Cooperative Group (AMLCG) 1999 trial. 2347 patients were evaluable for the present update. 243/2347 patients were &amp;lt;60 years of age and had unfavorable cytogenetics [com…

Oncologymedicine.medical_specialtybusiness.industrySurrogate endpointmedicine.medical_treatmentImmunologyMyeloid leukemiaCell BiologyHematologyHematopoietic stem cell transplantationBiochemistrylaw.inventionLog-rank testTransplantationRandomized controlled triallawhemic and lymphatic diseasesInternal medicineImmunologymedicineObservational studySiblingbusiness
researchProduct

Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3 -ITD Positive A…

2015

Abstract Background: Activating mutations in receptor tyrosine kinases like FLT3 (FLT3mut) lead to an aberrant signal transduction thereby causing an increased proliferation of hematopoietic cells. Internal tandem duplications (FLT3-ITD) or mutations in the tyrosine kinase domain (FLT3-TKD) occur in about 25% of younger adult patients (pts) with acute myeloid leukemia (AML), with FLT3 -ITD being associated with an unfavourable outcome. FLT3mut present an excellent target for small molecule tyrosine kinase inhibitors (TKI). The multi-targeted kinase inhibitor midostaurin (PKC412) is currently under investigation as a FLT3-inhibitor in combination with intensive chemotherapy. Monitoring of th…

Oncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologyHematopoietic stem cell transplantationBiochemistryChemotherapy regimenTargeted therapychemistry.chemical_compoundchemistryMaintenance therapyInternal medicinePharmacodynamicsmedicineCytarabineMidostaurinbusinessNeoadjuvant therapymedicine.drugBlood
researchProduct

cis-Dichloroplatinum(II) complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-ones: Synthesis and cytotoxicity in human cancer cell lines in vitro

2013

A novel family of cisplatin-type complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-one topoisomerase inhibitor via a polymethylene chain and their nonplatinated counterparts were prepared. Their potential cytotoxicity was assessed in three human colorectal cancer cell lines HCT 116, SW480 and HT-29 and compared to the reference molecules cisplatin and oxaliplatin. Platinated compounds were poorly active whilst nonplatinated dibenzo[c,h][1,6]naphthyridin-6-one moieties exhibited higher cytotoxic properties than cisplatin and oxaliplatin whatever the length of the polymethylene chain; molecules containing the tri- and hexamethylene chain length were the most cytotoxic.

Organoplatinum Compoundsmedicine.drug_classStereochemistryAntineoplastic AgentsStructure-Activity RelationshipCell Line TumorDrug DiscoverymedicineHumansCytotoxic T cellMoleculeNaphthyridinesCytotoxicityCell ProliferationPharmacologyCisplatinDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryGeneral MedicineHCT116 CellsIn vitroOxaliplatinCell cultureDrug Screening Assays AntitumorHT29 CellsTopoisomerase inhibitormedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

Association between sleep-disordered breathing and periodontitis: a meta-analysis

2022

Systemic inflammation is a feature of sleep-disordered breathing (SDB) as well as periodontitis. The association between SDB and periodontitis, however, has been inconsistent in previous studies. In order to fully evaluate the above association, we conducted a meta-analysis. Observational studies related to the aim of the meta-analysis were identified by search of PubMed, Embase, Web of Science, Wanfang, and CNKI databases. Only studies with SDB diagnosed with the objective polysomnography examination were included. The results were analyzed using a random-effects model that incorporated potential heterogeneity between studies. Ten cross-sectional or case-control studies with 43,296 partici…

Otorhinolaryngology2014 national institutes of health consensus criteriaSurgeryhematopoietic cell transplantationoral chronic graft-versus-host diseaseGeneral Dentistryoral mucosal diseaseUNESCO:CIENCIAS MÉDICASMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Stem cell-secreted factor therapy regenerates the ovarian niche and rescues follicles.

2021

Background Ovarian senescence is a normal age-associated phenomenon, but increasingly younger women are affected by diminished ovarian reserves or premature ovarian insufficiency. There is an urgent need for developing therapies to improve ovarian function in these patients. In this context, previous studies suggest that stem cell–secreted factors could have regenerative properties in the ovaries. Objective This study aimed to test the ability of various human plasma sources, enriched in stem cell–secreted factors, and the mechanisms behind their regenerative properties, to repair ovarian damage and to promote follicular development. Study Design In the first phase, the effects of human pla…

Ovarian CortexOvaryBone Marrow CellsPrimary Ovarian InsufficiencyPremature ovarian insufficiencyHematopoietic Cell Growth Factors03 medical and health sciencesMicePlasma0302 clinical medicineOvarian FollicleMice Inbred NODGranulocyte Colony-Stimulating FactorMedicineAnimalsHumans030212 general & internal medicinePlatelet activationOvarian ReserveStem Cell Factor030219 obstetrics & reproductive medicinebusiness.industryCell growthStem CellsOvaryInfant NewbornObstetrics and GynecologyBone Marrow Stem CellCell cycleFetal BloodDisease Models Animalmedicine.anatomical_structureCancer researchHeterograftsFemaleStem cellbusinessAmerican journal of obstetrics and gynecology
researchProduct

Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

2021

Abstract Background Little is known about characteristics of seasonal human coronaviruses (HCoVs) (NL63, 229E, OC43, and HKU1) after allogeneic stem cell transplantation (allo-HSCT). Methods This was a collaborative Spanish and European bone marrow transplantation retrospective multicenter study, which included allo-HSCT recipients (adults and children) with upper respiratory tract disease (URTD) and/or lower respiratory tract disease (LRTD) caused by seasonal HCoV diagnosed through multiplex polymerase chain reaction assays from January 2012 to January 2019. Results We included 402 allo-HSCT recipients who developed 449 HCoV URTD/LRTD episodes. Median age of recipients was 46 years (range,…

PNEUMONIAMalevirusesmedicine.medical_treatmentseasonal human coronavirusHematopoietic stem cell transplantationmedicine.disease_causeDISEASElaw.inventionCoronavirus OC43 HumanCLINICAL CHARACTERISTICSlawCoronavirus 229E HumanRisk FactorsImmunology and AllergyChildRespiratory Tract InfectionsNL63 INFECTIONSCoronavirusOUTCOMESRespiratory tract infectionsSYNCYTIAL VIRUSHazard ratioHematopoietic Stem Cell Transplantationvirus diseasesupper and lower respiratory tract diseaseHCoV-NL63HCoV-229Erespiratory systemMiddle AgedIntensive care unitHospitalizationimmunocompromisedsurgical procedures operativeInfectious Diseasesmedicine.anatomical_structureAcademicSubjects/MED00290Child PreschoolCohortFemaleSeasonsCoronavirus InfectionsRare cancers Radboud Institute for Health Sciences [Radboudumc 9]allogeneic hematopoietic stem cell transplantation; community-acquired respiratory virus; HCoV-229E; HCoV-HKU1; HCoV-NL63; HCoV-OC43; immunocompromised; immunodeficiency score index; multiplex PCR assay; seasonal human coronavirus; upper and lower respiratory tract diseaseAdultmedicine.medical_specialtyHCoV-OC43AdolescentDIAGNOSISCHINAHCoV-HKU1BetacoronavirusAll institutes and research themes of the Radboud University Medical Centerstomatognathic systemInternal medicinemedicineMajor ArticleRHINOVIRUSHumansallogeneic hematopoietic stem cell transplantationAgedRetrospective Studiescommunity-acquired respiratory virusbusiness.industryInfantmultiplex PCR assayTransplantationCoronavirus NL63 HumanPARAINFLUENZA VIRUSbusinessimmunodeficiency score indexRespiratory tract
researchProduct

FUSED PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS TOPOISOMERASE I INHIBITORS

2012

PYRROLO[23-b]PYRIDINE TOPOISOMERASE I INHIBITORSSettore CHIM/08 - Chimica Farmaceutica
researchProduct